Healthcare, Pharma & Life Sciences

Berlin – October 16, 2026 -- Aignostics has launched HETA Clinical, a family of pan-cancer AI products aimed at the 10% to 20% of molecular tests that pathologists estimate fail because tissue contains too little tumor.

The first four products analyze whole slide H&E images across the pathology workflow, from intake and evaluation through to molecular testing. The company says the suite helps labs prioritize cases, cut turnaround time and confirm sufficient tumor content before molecular testing begins.

Four products target slide quality, tumor presence, mitoses and cellularity

HETA Quality Control measures slide quality before analysis and identifies a range of quality issues. HETA Tumor Detect annotates tumor regions and flags cases likely to contain tumor at scanning, so those cases are read first and additional stains can be ordered at intake.

Boston – October 16, 2026 -- Perceptive Discovery has become the first US provider able to run astatine-211 (At-211) radiopharmaceutical development studies, now available at its US and UK sites through a collaboration with Atley Solutions.

First Atley C100 module purifies At-211 at QMUL laboratory in London

At Perceptive Discovery's laboratory at Queen Mary University of London (QMUL), the first Atley C100 module in the collaboration is installed. It has been used to purify At-211 from an irradiated bismuth-209 target.

A second Atley C100 module is expected at the company's Needham, Massachusetts facility later this month. The Atley C100 is an automated manufacturing platform built specifically for At-211 radiopharmaceuticals.

Indianapolis – October 16, 2026 -- Eli Lilly and Company (NYSE: LLY) will publish its third-quarter 2026 financial results on October 16, 2026, and will discuss the numbers on a conference call the same day.

Lilly schedules a 10 a.m. Eastern call for investors and media

The conference call begins at 10 a.m. Eastern time. Lilly will use it to detail the company's financial performance for the quarter with the investment community and media.

Lilly opens the live webcast to the general public

Investors, media and the general public can follow the call through a live webcast. Lilly will post the access link on its investor relations website, and a replay will be available there after the call ends.

The announcement gives no financial figures, guidance or earnings metrics ahead of the October 29 release.

SAN DIEGO – October 16, 2026 -- QuidelOrtho Corporation (Nasdaq: QDEL) has granted restricted stock units covering an aggregate of 50,323 shares of its common stock to two newly hired, non-executive employees.

Compensation Committee approves grants under 2026 Inducement Plan

The Compensation Committee of the company's Board of Directors approved the awards, which carry a grant date of October 16, 2026. They were issued under the company's 2026 Inducement Plan as an inducement material to each employee's entering into employment with the company.

The grants comply with Nasdaq Listing Rule 5635(c)(4), which governs equity awards made to individuals as an inducement to join a listed company.

Sheridan – October 16, 2026 -- The global cancer diagnostics market is valued at USD 29.3 billion in 2026 and is projected to reach USD 41.5 billion by 2031, a CAGR of 7.2%, according to a new study by Wissen Research.

Demand starts with patient volume. The International Agency for Research on Cancer counted about 20 million new cancer cases and 9.7 million cancer deaths worldwide in 2022, and expects annual new cases to pass 35 million by 2050. Each patient may need screening, diagnosis, staging, molecular characterization and follow-up.

Rancho Cucamonga – October 16, 2026 -- Inland Empire Health Plan (IEHP) ranked No. 34 on the 2026 Fortune and Great Place To Work Best Workplaces in Health Care list, its fifth consecutive year on the ranking.

Employee survey returns 87% favorable rating at IEHP

The 2026 Great Place To Work survey went to more than 3,800 IEHP team members. In the survey, 87% of respondents said the health plan is a great place to work. IEHP earned Great Place To Work certification in April for the sixth year in a row.

Glendale, Calif. – October 16, 2026 -- Reveleer has appointed Jean-Luc ("JL") Neptune, MD, MBA, as Chief Medical Officer to lead clinical strategy across risk adjustment, quality, and member management programs serving 12 million covered lives.

Neptune will set clinical direction for Reveleer products and shape the company's approach to AI, value-based care, and health care payment reform. He brings more than 20 years of experience putting new technology in front of clinicians at the point of care, first as a physician and later as a digital health founder.

Reveleer cites a gap between AI adoption and operational readiness

Citing its own 2026 State of Technology in Value-Based Care report, Reveleer says AI adoption has outpaced operational readiness. Health plans, it argues, need AI that scales quickly and remains transparent enough to trust.

Arlington – October 16, 2026 -- The Bone Health and Osteoporosis Foundation (BHOF) has named Kenneth G. Saag, M.D., M.Sc., North American Editor-in-Chief of Osteoporosis International (OI) for a five-year term starting Dec. 15, 2026.

Saag will serve alongside Professor René Rizzoli, M.D., Editor-in-Chief of the journal's European office. The two will set editorial direction with the journal's editors, Editorial Review Board, authors, reviewers and publisher. Saag will also oversee Archives of Osteoporosis in collaboration with the International Osteoporosis Foundation (IOF).

Ipswich, Mass. – October 16, 2026 -- New England Biolabs (NEB) has secured co-exclusive rights to sell seqWell's TnX Transposase and the right to manufacture the enzyme and include it in NEB kits and products, under a strategic partnership announced alongside the commercial launch of TnX Transposase (Unloaded).

NEB gains sales and manufacturing rights under the agreement

The deal gives NEB two rights: co-exclusive sales of TnX Transposase, and manufacturing of TnX for incorporation into its own kits. seqWell keeps selling TnX-based library preparation kits through its own channel.

NEB cites more than 50 years of enzyme manufacturing and quality control as its contribution. seqWell supplies the engineered enzyme and its transposase expertise.

Westlake, Texas – October 16, 2026 -- Virbac has donated more than 29,000 doses of IVERHART MAX Chews to KC Pet Project, the municipal animal shelter for Kansas City, Missouri, to protect its dogs against heartworm disease and intestinal parasites.

Shelter treats 300 heartworm-positive dogs while screening 8,263 intakes

KC Pet Project cares for more than 16,000 pets each year. It took in 8,263 dogs over the past 12 months, and each receives preventive care at intake. The donation supports that standard of care for every dog entering the shelter.

The shelter is currently treating about 300 dogs diagnosed with heartworm while in its care, according to Dr. Heather Kennedy, chief veterinary officer of KC Pet Project.